Search Results

An international collaboration between Bruce Power, Isogen and ITM Isotope Technologies Munich SE, announced the commencement of commercial production of lutetium-177.

ITM Medical Isotopes GmbH, a subsidiary of the biotechnology and radiopharmaceutical group of companies ITM Isotopen Technologien München AG (ITM), Bruce Power, an electricity company, and IsoGen, a joint venture between the two nuclear energy companies Framatome and Kinectrics, announced today that Bruce Power and IsoGen have set the first critical milestone for a reliable and consistent irradiation service which will be provided to ITM exclusively for 15 years

An international collaboration between Bruce Power, Isogen and ITM Isotope Technologies Munich SE, announced the commencement of commercial production of lutetium-177.

Core One Labs Inc.,, announces that its subsidiary, Core Isogenics Inc., has harvested 345 pounds of flower from its indoor facility at 9501 Commerce Way in Adelanto.

Lifestyle Delivery Systems Inc. announces that Core Isogenics Inc., the Company’s wholly-owned subsidiary focused on developing isogenic seed strains and automated cultivation methods for the cannabis industry (“Core Isogenics”), was issued both a Temporary Nursery License and a Cultivation License by the Bureau of Cannabis Control of California (the “Temporary Licenses”).

Lifestyle Delivery Systems Inc. announces that its wholly-owned subsidiary, Core Isogenics Inc. has begun nursery operations at the Adelanto facility.

Core One Labs Inc. (CSE: COOL), (OTCQX: CLABF), (Frankfurt: LD6, WKN: A14XHT) (“COOL” or the “Company”) announces that its wholly-owned subsidiary, Core Isogenics Inc., has completed its second and third on-going harvests at the Adelanto facility.

An international collaboration between Bruce Power, Isogen, and ITM Isotope Technologies Munich SE, announced a milestone marking the first instance lutetium-177, a short-lived medical isotope, has been produced in a commercial nuclear power reactor.

ITM Isotope Technologies Munich SE announced that its partners Bruce Power and Isogen have completed the installation of a groundbreaking Isotope Production System, becoming the first power reactor in the world with the installed capability to produce Lutetium-177, a medical isotope used in the treatment of various cancers, such as neuroendocrine tumors and prostate cancer.